- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07681193
Effects of Whole Body Vibration on Quadriceps Function, Landing Biomechanics, and Performance in Individuals With ACL Reconstruction
25. juni 2026 oppdatert av: University of North Carolina, Chapel Hill
Use of Whole-body Vibration to Acutely Improve Landing Biomechanics In Individuals With Anterior Cruciate Ligament Reconstruction (ACLR)
Individuals who undergo anterior cruciate ligament reconstruction (ACLR) are at heightened risk of secondary anterior cruciate ligament (ACL) injury (e.g.
additional injury to the ACL in either knee).
One of the primary physiological consequences of ACLR is the presence of quadriceps dysfunction (i.e.
reduced activation and strength) which has been linked to altered gait and landing biomechanics.
Aberrant landing biomechanics have been associated with an increased risk of both primary and secondary ACL injury, thus additional research is needed to evaluate the efficacy of treatments aimed to reduce quadriceps dysfunction and restore adequate landing biomechanics in attempts to reduce secondary ACL injury.
Whole-body Vibration (WBV) has demonstrated success in improving quadriceps function and gait biomechanics in individuals with ACLR, however its effectiveness on landing biomechanics is unknown.
To evaluate the acute effects of WBV on landing biomechanics in those with ACLR, a non-randomized crossover-controlled trial was conducted to determine if a single bout of WBV improved landing biomechanics greater than a control condition.
Participants completed two separate testing sessions (separated by at least one week) in which measures of quadriceps function and landing biomechanics were assessed before and after either a control (no WBV) or WBV intervention.
Separate linear mixed-effects models of post-test values for each dependent outcome were conducted with condition (control vs WBV) and limb (ACLR vs Uninvolved) as an interaction term, and each condition pre-test values and time post-ACLR as fixed effect covariates and a random effect of subject.
The investigators expect to observe a significant improvement in landing biomechanics following WBV compared to the control condition.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
36
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Univesrity of North Carolina at Chapel HIll MOTION Science Institute
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Between the ages of 18-35
- History of primary, unilateral ACLR
- Medically cleared for unrestricted physical activity
Exclusion Criteria:
- More than 5 years removed from ACLR
- Currently pregnant
- History of other lower extremity surgery
- History of lower extremity injury in previous 6 months
- History of neurological disorder
- Maximal isometric quadriceps torque > 3.0 Nm/kg in the ACLR limb
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Whole body vibration followed by No Intervention (Control)
Participants in this arm will receive Whole Body Vibration followed by a washout period of 1 week, then receive the Sham Whole body vibration (Control).
Each condition will be evaluated in a single session (i.e.
acute effects).
|
Participants will stand on a WBV platform in a mini-squat position while vibration is applied during six 60-second bouts with 2 minutes of rest between each bout.
WBV will be delivered at an acceleration of 2g and a frequency of 30 Hz.
Participants will stand on a WBV platform in a mini-squat position during six 60-second bouts with 2 minutes of rest between each bout.
No vibration will be applied.
|
|
Eksperimentell: Sham Whole body vibration (Control) followed by Whole Body Vibration
Participants in this arm will receive Sham Whole body vibration (Control) followed by a washout period of 1 week, then receive Whole Body Vibration.
Each condition will be evaluated in a single session (i.e.
acute effects).
|
Participants will stand on a WBV platform in a mini-squat position while vibration is applied during six 60-second bouts with 2 minutes of rest between each bout.
WBV will be delivered at an acceleration of 2g and a frequency of 30 Hz.
Participants will stand on a WBV platform in a mini-squat position during six 60-second bouts with 2 minutes of rest between each bout.
No vibration will be applied.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Internal Knee Adduction Moment (KAM)
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Peak value during landing in both single-leg and double-leg tasks averaged over 3 trials and normalized to the product of body weight and height
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
|
Internal Knee Extension Moment (KEM)
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Peak value during landing in both single-leg and double-leg tasks averaged over 3 trials and normalized to a product of body weight*height
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
|
Knee Flexion Angle (KFA)
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Peak value during landing in both single-leg and double-leg tasks averaged over 3 trials
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dynamic Postural Control
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Time-to-stabilization during single-leg landing
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
|
Vertical Ground Reaction Force
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Peak value during landing in both single-leg and double-leg tasks
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
|
Frontal Plane Kinematics
Tidsramme: Separate values prior to and immediately following the intervention (within 5 minutes).
|
Peak value during landing in both single-leg and double-leg tasks
|
Separate values prior to and immediately following the intervention (within 5 minutes).
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Derek Dewig, University of North Carolina, Chapel Hill
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. september 2021
Primær fullføring (Faktiske)
22. april 2022
Studiet fullført (Faktiske)
10. mai 2022
Datoer for studieregistrering
Først innsendt
10. juni 2026
Først innsendt som oppfylte QC-kriteriene
25. juni 2026
Først lagt ut (Faktiske)
2. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 21-0305
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Deidentified individual data that supports the results will be shared beginning 9 and continuing for 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD-delingstidsramme
IPD will be available beginning 9 and continuing for 36 months following publication.
Tilgangskriterier for IPD-deling
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .